DHTKD1 Mutations Cause 2-Aminoadipic and 2-Oxoadipic Aciduria  by Danhauser, Katharina et al.
REPORT
DHTKD1 Mutations Cause
2-Aminoadipic and 2-Oxoadipic Aciduria
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Abnormalities in metabolite profiles are valuable indicators of underlying pathologic conditions at the molecular level. However, their
interpretation relies on detailed knowledge of the pathways, enzymes, and genes involved. Identification and characterization of their
physiological function are therefore crucial for our understanding of human disease: they can provide guidance for therapeutic inter-
vention and help us to identify suitable biomarkers for monitoring associated disorders. We studied two individuals with 2-aminoadipic
and 2-oxoadipic aciduria, a metabolic condition that is still unresolved at the molecular level. This disorder has been associated with
varying neurological symptoms. Exome sequencing of a single affected individual revealed compound heterozygosity for an initiating
methionine mutation (c.1A>G) and a missense mutation (c.2185G>A [p.Gly729Arg]) in DHTKD1. This gene codes for dehydrogenase
E1 and transketolase domain-containing protein 1, which is part of a 2-oxoglutarate-dehydrogenase-complex-like protein. Sequence
analysis of a second individual identified the same missense mutation together with a nonsense mutation (c.1228C>T [p.Arg410*])
in DHTKD1. Increased levels of 2-oxoadipate in individual-derived fibroblasts normalized upon lentiviral expression of the wild-type
DHTKD1 mRNA. Moreover, investigation of L-lysine metabolism showed an accumulation of deuterium-labeled 2-oxoadipate only in
noncomplemented cells, demonstrating that DHTKD1 codes for the enzyme mediating the last unresolved step in the L-lysine-
degradation pathway. All together, our results establish mutations in DHTKD1 as a cause of human 2-aminoadipic and 2-oxoadipic
aciduria via impaired turnover of decarboxylation 2-oxoadipate to glutaryl-CoA.L-lysine degradation is a complex multistep mechanism
involving mitochondrial, cytosolic, and peroxisomal
enzymes. It converges with the degradative pathways
of L-hydroxylysine and L-tryptophan at the levels of
2-aminoadipic-6-semialdehyde and 2-oxoadipate, respec-
tively (Figure 1). Although themolecular causes of most in-
herited deficiencies of lysine degradation have been eluci-
dated, those of 2-aminoadipic and 2-oxoadipic aciduria
(MIM 204750) remain to be explained. Over 20 individuals
with this metabolic disease are known. More than half of
them are asymptomatic, whereas others have developed
mild to severe intellectual disability, muscular hypotonia,
developmental delay, ataxia, and epilepsy.1,2 A defect in
2-oxoadipate dehydrogenase was first suggested as an
underlying cause, but there was no experimental evidence.
Furthermore, it was shown that the 2-oxoglutarate-
dehydrogenase complex (OGDHc) also has substrate
specificity for 2-oxoadipate.3 Individuals with inherited
2-oxoglutarate-dehydrogenase deficiency usually present
in the newborn period or infancy with severe neurological
symptoms, as well as elevated 2-oxoglutarate and lactate.4
Fiermonte and coworkers suggested a deficiency of the
human 2-oxoadipate mitochondrial carrier as the under-
lying cause.5
To unravel the metabolic origin of 2-aminoadipic and
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disease. Both were born to nonconsanguineous parents
after an uneventful pregnancy and delivery and had an
unremarkable family history.
Individual 1, a girl, presented with moderately delayed
psychomotor development (sitting alone at age 10months
and walking alone at age 25 months) in infancy, and this
improved by physiotherapy and occupational therapy.
Metabolic analysis at the age of 2 years showed elevated
2-oxoadipate (range ¼ 10–120 mmol/mol creatinine) and
2-hydroxyadipate (range ¼ 5–40 mmol/mol creatinine) in
urine; these are usually not detected. The plasma concen-
tration of 2-aminoadipate was also elevated (120 mmol/l).
Moderate protein restriction was introduced but did not
influence the disease course and was thus discontinued.
Serial cranial magnetic-resonance-imaging studies did not
reveal anymorphological abnormalities, andneuropsycho-
logical testing at the age of 8 years revealed an intelligence
quotient (IQ) of 117. At 11 years of age, she was diagnosed
with attention deficit hyperactivity disorder. Symptoms
improved after implementation of methylphenidate.
At the age of 14 years, her health is in excellent condition,
and she is attending regular school and is following
a normal diet. Neurological examination was normal.
Individual 2, a girl, presented with microcephaly, mild
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Figure 1. Proposed Multicompartmen-
tal Degradative Pathway of L-lysine
L-Lysine degradation is initiated by either
peroxisomal a-deamination (pipecolate
pathway) or mitochondrial ε-deamination
(saccharopine pathway). Both pathways
converge in 2-aminoadipate semialde-
hyde, which is subsequently metabolized
to 2-aminoadipate and 2-oxoadipate. Our
data strongly indicate that DHTKD1 is
part of a 2-oxoglutarate-dehydrogenase-
complex (OGDHc)-like enzyme and is
involved in the decarboxylation of 2-oxoa-
dipate to glutaryl-CoA. A minor route for
this reaction via the tricarboxylic-acid
(TCA)-cycle enzyme OGDHc might exist
but does not compensate for the lack of
DHTKD1. Succinyl-CoA and glutaryl-CoA
are known to inhibit OGDHc (not shown).
DTHKD1 might be an interesting drug
target for glutaric aciduria type I, which is
caused by inherited deficiency of glutaryl-
CoA dehydrogenase (GCDH). MIM num-
bers of inherited diseases of the lysine
degradative pathway are provided (e.g.,
MIM 245130 for 2-aminoadipic and
2-oxoadipic aciduria). Dotted lines indi-
cate multiple enzymatic steps. The
following abbreviations are used: AADAT,
2-aminoadipate transaminase; AASDH,
2-aminoadipate-6-semialdehyde dehydro-
genase; AASS, 2-aminoadipate-6-semialde-
hyde synthetase; DHTKD1, proposed E1
subunit of an OGDHc-like complex; and
PIPOX, pipecolate oxidase. Mitochondrial
transporters are not shown in this figure.9 months and walking alone at the age of 22 months), and
predominant speech delay of unknown origin in early
childhood. Sensorineural hearing loss was excluded.
When she was 2 years old, metabolic analyses of urine
and plasma revealed the characteristic biochemical profile
of 2-aminoadipic and 2-oxoadipic aciduria (2-oxoadipate,
520–970 mmol/mol creatinine; 2-hydroxyadipate, 100–
150 mmol/mol creatinine; 2-aminoadipate, elevated).
Moderate protein restriction was transiently introduced
but did not influence the disease course. At the age of 12
years, she still has significant problems with expressive
and receptive speech (limited active and passive vocabu-
lary, dyslalia, and dysgrammatism). Her IQ is 87. Except
for mild muscular hypotonia, neurological examination
was normal.
Written informed consent was obtained from all partici-
pants or their guardians at the recruiting center, and the
study was approved by the ethical committee at the
Technical University of Munich.
We performed exome sequencing as described previ-
ously6 to identify mutations responsible for 2-aminoadipic
and 2-oxoadipic aciduria in individual 1. In brief, exonic
sequences were enriched with the use of the SureSelect
Human All Exon 50 Mb kit from Agilent and were sub-
sequently sequenced as 100 bp paired-end runs on aThe American JouHiseq2000 system (Illumina). Data analysis included read
alignment with the Burrows-Wheeler Aligner (version
0.5.8) and variant calling with SAMtools (version 0.1.7).
We produced 8.98 Gb of mappable sequences with an
average exome coverage of 102.83, and>91% of the target
was covered more than 203.
We next applied additional filters under the assump-
tion of autosomal-recessive inheritance and a low allele
frequency of causal mutations in controls. Accordingly,
we excluded variants with a minor allele frequency
(MAF) > 0.4% in SNP databases (HapMap and 1000
Genomes) and in 1,458 exomes from individuals with
unrelated phenotypes.
This analysis identified eight candidate genes carrying
predicted compound heterozygous or homozygous vari-
ants (Table 1). No mutation was detected in ODC, mainly
excluding a dysfunctional 2-oxoadipate mitochondrial
carrier as the underlying cause.5 Of the eight candidates,
three (ADAMTS10, AIRE, and C8orf38) had been previ-
ously linked to unrelated phenotypes and were therefore
considered to be not involved. Among the remaining
five genes (DHTKD1, OVOS2, CAMTA2, LPPR3, and
RADIL), only one, DHTKD1 (RefSeq accession number
NM_018706.5), carried two probably pathogenic variants
as predicted by in-silico-analysis software (PolyPhen-2rnal of Human Genetics 91, 1082–1087, December 7, 2012 1083
Table 1. Variants Identified in an Individual with 2-Aminoadipic
and 2-Oxoadipic Aciduria
Number of Variants
Synonymous 11,229
Nonsynonymous 10,252
Rare nonsynonymous 313
Genes withR two nonsynonymous variants 8
‘‘Rare’’ indicates a frequency < 0.4% in 1,458 control exomes, HapMap, and
the 1000 Genomes Project. Nonsynonymous variants include missense,
nonsense, stoploss, and splice-site mutations, as well as insertions and dele-
tions.and MutationTaster7). The first mutation, c.1A>G
(p.Met1?), affects the start codon and might cause out-
of-frame usage of the next AUG triplet 160 nucleotides
downstream; it is therefore expected to produce a nonfunc-
tional protein. The second mutation, c.2185G>A, is pre-
dicted to cause an amino acid exchange, p.Gly729Arg,
affecting an amino acid residue evolutionarily con-
served from Homo sapiens to Caenorhabditis elegans and
Drosophila melanogaster. This mutation is listed in dbSNP
(rs117225135) and was found in the National Heart,
Lung, and Blood Institute (NHLBI) Exome Variant ServerFigure 2. Pedigrees of Investigated Families and DHTKD1 Structur
(A) Mutation status of affected (closed symbols) and unaffected (ope
(B) Structure of DHTKD1 with localization and conservation of affec
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but no homozygous carriers among 5,379 individuals.
Investigation of the carrier status of the parents showed
that the c.1A>Gmutation is present on the maternal allele
but that the c.2185G>A mutation is absent from both the
maternal and the paternal allele (Figure 2).
Sanger sequencing of the DHTKD1 coding regions from
individual 2 with the use of intronic primers (sequences
are available upon request) identified compound heterozy-
gosity for an exon 7 nucleotide transition, c.1228C>T,
which is predicted to generate a stop codon (p.Arg410*),
as well as heterozygous mutation c.2185G>A, also
observed in individual 1. Both parents were found to carry
one mutation each in the heterozygous state. Identifica-
tion of DHTKD1 mutations in a second individual with
the same metabolic profile supports a causal role for these
mutations in the pathogenesis of 2-aminoadipic and
2-oxoadipic aciduria. A summary of the genetic, biochem-
ical, and clinical phenotype of individuals 1 and 2 is
provided in Table 2.
Although both individuals carried one predicted loss-of-
function allele, the effects of the sharedmissense mutation
on DHTKD1 activity were unclear. In order to confirm the
detrimental functional consequences of the c.2185G>A
(p.Gly729Arg) mutation and to verify the causal role ofe and Conservation of Identified Mutations
n symbols) family members.
ted amino acid residues of identified mutations.
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Table 2. Genetic, Biochemical, and Clinical Phenotype of Individuals with DHTKD1 Mutations
ID Sex
DHTKD1 Mutations Identified Biochemical Investigations Clinical Features
cDNA (RefSeq
NM_018706.5)
Protein (RefSeq
NP_061176) 2-OAa 2-OHAa 2-AAa
Age of
Diagnosis Clinical Presentation
1 female c.1A>G
c.2185G>A
p.Met1?
p.Gly729Arg
10–120 mmol/mol
creatinine
5–40 mmol/mol
creatinine
120 mmol/l 2 years moderate psychomotor
developmental delay
and attention deficit
hyperactivity syndrome
2 female c.1228C>T
c.2185G>A
p.Arg410*
p.Gly729Arg
520–970 mmol/mol
creatinine
100–150 mmol/mol
creatinine
above
normal
2 years slight psychomotor
developmental delay,
predominant speech
delay, and mild muscular
hypotonia
The following abbreviations are used: 2-OA, 2-oxoadipate; 2-OHA, 2-hydroxyadipate; and 2-AA, 2-aminoadipate.
aThe reference range is <5.
Figure 3. Metabolic Function of DHTKD1
Primary fibroblasts of several controls (C) and of individuals 1 and
2, as well as fibroblasts expressing wild-type DHTKD1 from indi-
viduals 1 and 2 (1-T and 2-T, respectively) and a healthy control
(C-T) were cultivated in MEM medium for 4 days. Fibroblasts
from the affected individuals showed increased intracellular and
extracellular levels of 2-oxoadipate. Expressions of wild-type
DHTKD1 in these cells reduced intracellular and extracellular
2-oxoadipate concentrations to the levels seen in metabolically
competent control fibroblasts. Data are presented as the mean
of five independent experiments 5 the standard deviation
(**p < 0.01, ***p < 0.001). Immunoblotting of the same cell lines
was performed on mitochondria-enriched samples. The antibody
against DHTKD1 (Sigma-Aldrich, SAB 1400619, dilution 1:1,000)
demonstrated increased levels of DHTKD1. An antibody against
the complex III core protein 2 (Abcam, ab14745, dilution
1:1,000) was used as a loading control.the identified variants in DHTKD1, we performed comple-
mentation experiments in fibroblast cell lines established
from both individuals 1 and 2. By using a feline-immuno-
deficiency-virus-based lentiviral system, we transduced an
expression vector (Genecopoeia) containing the cDNA of
DHTKD1 and a neomycin resistance gene as described
previously.8 Immunoblotting with an antibody against
DHTKD1 (Sigma-Aldrich) on mitochondria-enriched
samples confirmed higher protein levels after transduction
(Figure 3). Next, we cultivated primary fibroblasts, as well
as fibroblasts expressing wild-type DHTKD1, from individ-
uals 1 and 2 and from a healthy control in MEM medium
(PAA) containing 10% fetal calf serum (GIBCO, Life Tech-
nologies) and penicillin and streptomycin (PAA) for
4 days. Afterward, 2-oxoadipate levels were detected in cells
and media with the use of gas chromatography/mass spec-
trometry (GC/MS) according to a previously described
method9 (fragment ionm/z 302). Compared to the control
cell line (NHDF-neo, Lonza), both cell lines of the affected
individuals showed increased levels of 2-oxoadipate in cells
and media. Expressions of the wild-type DHTKD1 in fibro-
blasts of individuals 1 and 2 led to a strong decrease in intra-
cellular and extracellular 2-oxoadipate concentrations to
the levels of those in metabolically competent control
fibroblasts (Figure 3). To pinpoint the role of DHTKD1 in
lysine metabolism, we cultivated primary fibroblasts, as
well as fibroblasts expressing the wild-type DHTKD1, in
MEM medium as described above, but we supplemented
them with 4 mmol/l 4,4,5,5-d4-lysine (CDN Isotope). The
production of deuterium-labeled 2-oxoadipate was de-
tected by GC/MS9 (fragment ion m/z 306). Indeed,
4,4,5,5-d4-labeled 2-oxoadipate could be shown inmedium
and cells of individuals 1 and 2, whereas its levels were
strongly reduced when the wild-type DHTKD1 was ex-
pressed in these cells (Figure 4). In control fibroblast cells,
4,4,5,5-d4-labeled 2-oxoadipate was not detected. All
together, our data provide strong evidence that reduced
DHTKD1 activity is responsible for 2-aminoadipic and
2-oxoadipic aciduria in the investigated individuals.
We applied an unbiased exome-sequencing-based ap-
proach to identify DHTKD1 mutations as an underlyingThe American Joumolecular-genetic cause of a rare metabolic disorder,
2-aminoadipic and 2-oxoadipic aciduria. Although this
metabolic profile is extremely rare, elucidation of thernal of Human Genetics 91, 1082–1087, December 7, 2012 1085
Figure 4. d4-Oxoadipate Production by Fibroblasts
Several control (C) fibroblasts and fibroblasts from individuals 1
and 2 with compound heterozygous DHTKD1 mutations were
cultivated in MEM medium supplemented with 4 mM 4,4,5,5-
d4-lysine. Detection of d4-oxoapidate in cells and media showed
an overproduction of d4-oxoadipate in fibroblasts of individuals
1 and 2; this overproduction was reduced by the expression of
wild-type DHTKD1 (C-T, 1-T, and 2-T). Data are presented as the
mean of four independent measurements 5 the standard devia-
tion. *p < 0.05, **p < 0.01, ***p < 0.001.genetic defect and subsequent characterization of enzy-
matic activity of the gene product have provided new
insights into a basic cellular pathway of amino acid degra-
dation.
DHTKD1 is one of two known isoforms of the E1 subunit
of the OGDHc. It has been speculated that the 2-oxogluta-
rate-dehydrogenase-like proteins have different substrate
affinities.10 The OGDHc catalyzes the decarboxylation of
2-oxoglutarate to succinyl-CoA within the citrate cycle.
Our data suggest that DHTKD1 is part of an OGDHc-
like supercomplex responsible for the decarboxylation
of 2-oxoadipate to glutaryl-CoA within the common
degradative pathways of L-lysine, L-hydroxylysine, and
L-tryptophan.
In line with these findings, defective DHTKD1 activities
resulted in increased levels of 2-oxoadipate and 2-oxoami-
noadipate. In contrast to individuals who have other
inherited disorders of amino acid degradation and who
present with accumulating toxic metabolites and a severe
clinical phenotype, such as phenylketonuria (MIM
261600), maple syrup urine disease (MIM 248600), tyrosi-
nemia type I (MIM 276700), nonketotic hyperglycinemia
(MIM 605899), and glutaric aciduria type I (MIM
231670), the individuals investigated in this study dis-1086 The American Journal of Human Genetics 91, 1082–1087, Deceplayed rather mild and unspecific phenotypes. Of note,
both individuals carried the same missense mutation,
which might allow residual protein function. Therefore,
it can be speculated that either complete loss of function
leads to a more severe clinical phenotype or the mild clin-
ical phenotype is explained by the low toxicity of accumu-
lating metabolites. DHTKD1 is located one enzymatic step
above glutaryl-CoA dehydrogenase in the lysine degrada-
tive pathway. Deficiency of glutaryl-CoA dehydrogenase
causes glutaric aciduria type I, a cerebral organic acidemia
that causes a severe neurological phenotype if untreated.
Pharmacologic inhibition of DHTKD1 might be an inter-
esting new drug target for glutaric aciduria type I in
that it converts this disease into 2-aminoadipate and
2-oxoadipate aciduria, which has a less severe neurological
phenotype. Interestingly, it has been reported that an
apparent 2-aminoadipic aciduria also occurred during
an antiepilectic treatment with vigabatrin and was
probably caused by the inhibition of the metabolizing
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